NERV

Minerva NeurosciencesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$12.46

+162.3% vs current

Most likely

Base case

50%

Probability

Target price

$4.59

-3.4% vs current

B-

Bear case

30%

Probability

Target price

$2.50

-47.4% vs current

AI sentiment snapshot

Latest data as of 2026-03-11

AI commentary

Current market and analyst sentiment is negative: median analyst targets sit below the anchor price, reflecting concentrated clinical and financing risk. Filings (10‑K, 8‑K) and IR updates frame upcoming trial readouts and financing items as binary catalysts for rerating [#SERP-2] [#10-K-2026-03-11] [#8-K-2026-03-11].

RankAlpha Sentiment AI - 2026-03-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2027-03-11catalyst10‑K financing disclosures could extend runway and fund Phase‑3High impact

The 2026 Form 10‑K (filed 2026-03-11) documents private placement proceeds, warrants, and related liabilities tied to the Oct 2025 financing; these commitments could materially extend cash runway and fund the roluperidone Phase‑3 program if accessible and not contingent on further conditions [#10-K-2026-03-11].

2027-03-11catalystPhase‑3 roluperidone operational readout / interim update windowHigh impact

Company IR and 8‑K updates indicate enrollment completion; the next material company‑specific event is an efficacy/safety readout or interim operational update tied to the completed cohort and follow‑up window [#8-K-2026-03-11] [#SERP-3].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-03-11 • Updated nightlySource: Internal modelMethodology